search
Back to results

Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization

Primary Purpose

Uterine Fibroids

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Uterine Fibroid Embolization
Sponsored by
Gary Siskin, MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Uterine Fibroids focused on measuring Uterine Fibroids, Embolization

Eligibility Criteria

30 Years - 50 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. She is able to provide informed consent and sign the Institutional Review Board approved informed consent form.
  2. She is pre-menopausal and 30-50 years of age at the time of enrollment.
  3. She is not actively attempting to become pregnant for a minimum of 1 year after UFE, or practicing abstinence and willing to continue for a minimum of 1 year after UFE, or is surgically sterile.
  4. She is suffering from clinically significant symptoms attributed to the presence of uterine fibroids including abnormal menstrual bleeding and/or bulk-related symptoms including pelvic pain/discomfort, abdominal distension, urinary symptoms (including but not limited to increased urinary frequency or urinary hesitancy), and/or dyspareunia.

Exclusion Criteria:

  1. She has a history of pelvic malignancy.
  2. She is pregnant or intends to become pregnant within 12 months of the planned UFE procedure.
  3. She has had an abnormal PAP smear (anything other than normal or ASCUS - Atypical Squamous Cells of Unknown Significance) within 12 months of the planned UFE procedure.
  4. She has a coexisting condition that might explain the presenting symptoms (including but not limited to adenomyosis, endometrial hyperplasia, endometriosis, and complex ovarian cysts).
  5. She has evidence of current or recent pelvic inflammatory disease or uterine infection.
  6. She has another serious medical condition that might preclude full participation in the study to the desired endpoint (e.g., uncontrolled diabetes, malignancy, chronic obstructive pulmonary disease, myocardial infarction, congestive heart failure, etc.)
  7. She has a severe contrast allergy or renal insufficiency that would represent a contraindication to the administration of iodine-based or gadolinium-based contrast agents.
  8. She has a contraindication to magnetic resonance imaging (MRI).
  9. She has one or more MRI findings including a uterine size >20 cm in greatest length, a dominant fibroid with a greatest diameter >12 cm, an intracavitary submucosal fibroid, or non enhancing dominant fibroids.
  10. In the judgment of the investigator, she is unable or unlikely to be able to comply with the study procedures and requirements.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Embozene Microspheres

    Embosphere Microspheres

    Arm Description

    Patients will undergo the uterine fibroid embolization procedure with Embozene Microspheres as the embolic agent.

    Patients will undergo the uterine fibroid embolization procedure with Embosphere Microspheres as the embolic agent.

    Outcomes

    Primary Outcome Measures

    Fibroid Infarction Rate
    The primary effectiveness endpoint for this study is the proportion of patients with a global rate of infarction for all fibroids present within the uterus that is >90% as seen on contrast-enhanced MRI.

    Secondary Outcome Measures

    Symptom Severity
    The percentage of patients experiencing improvement in symptom severity after the uterine fibroid embolization procedure.
    Health-Related Quality of Life
    The percentage of patients experiencing improvement in health-related quality of life after the uterine fibroid embolization procedure.
    Uterine Volume
    The change in uterine volume as seen on MRI examinations performed 3 months after the embolization procedure.
    Dominant Fibroid Volume
    The change in dominant fibroid volume as seen on MRI examinations performed 3 months after the embolization procedure.
    Frequency of Adverse Events After Treatment
    The frequency of adverse events occurring after embolization will be monitored and reported.

    Full Information

    First Posted
    August 26, 2016
    Last Updated
    August 30, 2016
    Sponsor
    Gary Siskin, MD
    Collaborators
    Boston Scientific Corporation
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02884960
    Brief Title
    Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization
    Official Title
    Safety and Efficacy of Embozene® Microspheres for Uterine Fibroid Embolization Compared to Embosphere® Microspheres for Symptomatic Relief From Uterine Fibroids
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2016
    Overall Recruitment Status
    Unknown status
    Study Start Date
    October 2016 (undefined)
    Primary Completion Date
    October 2017 (Anticipated)
    Study Completion Date
    October 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Gary Siskin, MD
    Collaborators
    Boston Scientific Corporation

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to evaluate the safety and effectiveness of Embozene Microspheres compared with Embosphere Microspheres for the treatment of symptomatic uterine fibroids. A total of 118 patents with symptomatic uterine fibroids will be enrolled at 6 sites. Symptom severity, health-related quality of life, and the appearance of the fibroids will be assessed prior to treatment. Patients will then undergo the uterine fibroid embolization procedure with either Embosphere Microspheres or Embozene Microspheres, which will be randomly assigned. Clinical outcomes will be assessed 1 month, 3 months, 6 months and 12 months after the procedure, and imaging outcomes will be obtained 3 months after the procedure.
    Detailed Description
    The uterine fibroid embolization (UFE) procedure is an accepted, minimally invasive treatment option for patients with symptomatic uterine fibroids. Studies evaluating the outcomes after this procedure have established that the use of polyvinyl alcohol particles and Embosphere Microspheres is associated with best clinical and imaging outcomes. Embozene Microspheres represent a new embolic agent that is being evaluated for use for the treatment of symptomatic fibroids. The purpose of this study is to evaluate the safety and effectiveness of Embozene Microspheres compared with Embosphere Microspheres for the treatment of symptomatic uterine fibroids. A total of 118 patents with symptomatic uterine fibroids will be enrolled at 6 sites. A questionnaire designed to assess symptom severity and health-related quality of life in patients will be administered to patients at the time of enrollment. In addition, a contrast-enhanced magnetic resonance imaging (MRI) examination will be performed to confirm the diagnosis of fibroids. Patients will then undergo the uterine fibroid embolization procedure. The embolic agent used for the procedure (Embosphere Microspheres or Embozene Microspheres) will be randomly assigned. Patients will be seen 1 month, 3 months, and 6 months and contacted 12 months after the procedure so that the same questionnaire can be used to assess clinical outcomes. In addition, an MRI will be performed 3 months after the procedure to determine the imaging response to treatment.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Uterine Fibroids
    Keywords
    Uterine Fibroids, Embolization

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    118 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Embozene Microspheres
    Arm Type
    Experimental
    Arm Description
    Patients will undergo the uterine fibroid embolization procedure with Embozene Microspheres as the embolic agent.
    Arm Title
    Embosphere Microspheres
    Arm Type
    Active Comparator
    Arm Description
    Patients will undergo the uterine fibroid embolization procedure with Embosphere Microspheres as the embolic agent.
    Intervention Type
    Procedure
    Intervention Name(s)
    Uterine Fibroid Embolization
    Intervention Description
    This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
    Primary Outcome Measure Information:
    Title
    Fibroid Infarction Rate
    Description
    The primary effectiveness endpoint for this study is the proportion of patients with a global rate of infarction for all fibroids present within the uterus that is >90% as seen on contrast-enhanced MRI.
    Time Frame
    3 Months
    Secondary Outcome Measure Information:
    Title
    Symptom Severity
    Description
    The percentage of patients experiencing improvement in symptom severity after the uterine fibroid embolization procedure.
    Time Frame
    12 Months
    Title
    Health-Related Quality of Life
    Description
    The percentage of patients experiencing improvement in health-related quality of life after the uterine fibroid embolization procedure.
    Time Frame
    12 Months
    Title
    Uterine Volume
    Description
    The change in uterine volume as seen on MRI examinations performed 3 months after the embolization procedure.
    Time Frame
    3 Months
    Title
    Dominant Fibroid Volume
    Description
    The change in dominant fibroid volume as seen on MRI examinations performed 3 months after the embolization procedure.
    Time Frame
    12 Months
    Title
    Frequency of Adverse Events After Treatment
    Description
    The frequency of adverse events occurring after embolization will be monitored and reported.
    Time Frame
    12 Months

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    30 Years
    Maximum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: She is able to provide informed consent and sign the Institutional Review Board approved informed consent form. She is pre-menopausal and 30-50 years of age at the time of enrollment. She is not actively attempting to become pregnant for a minimum of 1 year after UFE, or practicing abstinence and willing to continue for a minimum of 1 year after UFE, or is surgically sterile. She is suffering from clinically significant symptoms attributed to the presence of uterine fibroids including abnormal menstrual bleeding and/or bulk-related symptoms including pelvic pain/discomfort, abdominal distension, urinary symptoms (including but not limited to increased urinary frequency or urinary hesitancy), and/or dyspareunia. Exclusion Criteria: She has a history of pelvic malignancy. She is pregnant or intends to become pregnant within 12 months of the planned UFE procedure. She has had an abnormal PAP smear (anything other than normal or ASCUS - Atypical Squamous Cells of Unknown Significance) within 12 months of the planned UFE procedure. She has a coexisting condition that might explain the presenting symptoms (including but not limited to adenomyosis, endometrial hyperplasia, endometriosis, and complex ovarian cysts). She has evidence of current or recent pelvic inflammatory disease or uterine infection. She has another serious medical condition that might preclude full participation in the study to the desired endpoint (e.g., uncontrolled diabetes, malignancy, chronic obstructive pulmonary disease, myocardial infarction, congestive heart failure, etc.) She has a severe contrast allergy or renal insufficiency that would represent a contraindication to the administration of iodine-based or gadolinium-based contrast agents. She has a contraindication to magnetic resonance imaging (MRI). She has one or more MRI findings including a uterine size >20 cm in greatest length, a dominant fibroid with a greatest diameter >12 cm, an intracavitary submucosal fibroid, or non enhancing dominant fibroids. In the judgment of the investigator, she is unable or unlikely to be able to comply with the study procedures and requirements.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Barbara MacDowell
    Phone
    518-262-5149
    Email
    macdowb@mail.amc.edu
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Gary Siskin, MD
    Organizational Affiliation
    Community Care Physicians
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization

    We'll reach out to this number within 24 hrs